Chemistry Reference
In-Depth Information
[407] Bernauer J, Poupon A, Aze J, Janin J. A docking analysis of the statistical physics of
protein-protein recognition. Phys Biol, 2005, 2: S17-S23.
[408] Bernauer J, Aze J, Janin J, Poupon A. A new protein-protein docking scoring function
based on interface residue properties. Bioinformatics, 2007, 23: 555-562.
[409] Lensink MF, Mendez R, Wodak SJ, Docking and scoring protein complexes: CAPRI 3rd
Edition. Proteins, 2007, 69: 704-718.
[410] Mendez R, Leplae R, Lensink MF, Wodak SJ. Assessment of CAPRI predictions in rounds
3-5 shows progress in docking procedures. Proteins, 2005, 60:150-69.
[411] De Las Rivas J and Fontanillo C, Protein-protein interaction networks: unraveling the
wiring of molecular machines within the cell, Briefings in functional genomics, 2012,
2:489-496.
[412] Vajda S, Hall DR and Kozakov D, Sampling and scoring: a marriage made in heaven,
2013, 81, 1874-1884.
[413] Hook LA, Stem cell technology for drug discovery and development, Drug Discovery
Today, 2012, 17: 336-342.
[414] Alison MR and Islam S. Attributes of adult stem cells. J. Pathol. 2009, 217:144-1460.
[415] Copelan EA, Hematopoietic stem-cell transplantation. N. Engl. J. Med., 2006, 354:1813-
1826.
[416] Czechowicz, A. and Weissman, IL. Purified hematopoietic stem cell transplantation: the
next generation of blood and immune replacement. Immunol. Allergy Clin. North Am.
2010, 30: 159-171
[417] Ruin LL and Haston KM. Stem cell biology and drug discovery. BMC Biol., 2011, 9: 42-
43.
[418] Clark DE, What has virtual screening ever done for drug discovery? Exp. Opin. Drug
Discov., 2008, 3: 841-851.
[419] Shoichet, B. K. Virtual screening of chemical libraries. Nature, 2004, 432; 862-865.
[420] Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov.
2002, 1: 882-894.
[421] Mestres J. Virtual screening: a real screening complement to highthroughput screening.
Biochem. Soc. Trans., 2002, 30: 797-799.
[422] Phatak SS, Stephan CC, Cavasotto CN. High-throughput and
in silico
screenings in drug
discovery. Exp. Opin. Drug Discov., 2009, 4: 947-959.
[423] Davies JW, Glick M, Jenkins JL. Streamlining lead discovery by aligning
in silico
and
high-throughput screening. Curr. Opin. Chem. Biol., 2006, 10: 343-351.
[424] Hawkins PCD, Skillman AG, Nicholls A. Comparison of shape-matching and docking as
virtual screening tools. J. Med. Chem., 2007, 50: 74-82.
[425] Tanrikulu Y, Schneider G. Pseudoreceptor models in drug design: bridging ligand- and
receptor-based virtual screening. Nat. Rev. Drug Discov., 2008, 7: 667-677.
[426] Clark RD. Prospective ligand- and target-based 3D QSAR: state of the art 2008. Curr. Top.
Med. Chem., 2009, 9: 791-810.
[427] Koutsoukas A, Simms B,Kirchmair J, Bond PJ, Whitmore AV, Zimmer S, Young MP,
Jenkins JL, Glick M, Glen RC. Bender, A. From
in silico
target prediction to multi-target
drug design: Current databases, methods and applications. J. Proteomics, 2011, 74: 2554-
2574.
